Geron Corporation (Nasdaq: GERN) will announce its financial results for the 2008 first quarter on Tuesday, April 29, 2008, after the closing of the equity market. Thomas B. Okarma, Ph.D., M.D., Geron’s chief executive officer, and David L. Greenwood, Geron’s chief financial officer, will host a conference call for analysts and investors on Wednesday, April 30 at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time.

Participants can access the conference call via telephone by dialing 866-383-8009 (U.S.) or 617-597-5342 (international). The passcode is 38430133. A live audio-only Webcast is also available through a link that is posted on the conferences page in the investor relations section of Geron’s Web site at http://www.geron.com. The audio Web broadcast of the conference call will be available for replay through May 30, 2008.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

Contacts:

Media and Investors:
Russo Partners, LLC
David Schull, 858-717-2310
david.schull@russopartnersllc.com
or
Geron
David L. Greenwood, Chief Financial Officer, 650-473-7765
info@geron.com